1 77.066


PT Schering Indonesia
Obat Kulit
Beri rekomendasi

ELOCON Cream, Ointment and Lotion 0.1% are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses, such as psoriasis and atopic dermatitis.

Kontra Indikasi:
ELOCON Cream, Ointment and Lotion 0.1% are contraindicated in patients who are sensitive to mometasone furoate, to other corticosteroids or to any component of these preparations.

Each gram ELOCON Cream 0.1% contains 1 mg mometasone furoate
Each gram ELOCON Lotion 0.1% contains 1 mg mometasone furoate
Each gram ELOCON Ointment 0.1% contains 1 mg mometasone furoate

Mometasone furoate, a synthetic corticosteroid, exhibits anti-inflammatory, antipruritic and vasocon-strictive properties.

Dosage and Administration:
A thin film of ELOCON Cream or Ointment 0.1% should be applied to the affected skin areas once daily.
Do not use occlusive dressing.

Apply a few drops of ELOCON Lotion to affected skin once daily; massage gently and thoroughly until the medication disappears.

Adverse Reaction:
Local adverse reaction reported very rarely with ELECON Cream 0.1% include paresthesia, pruritus and signs of skin atrophy.

Local adverse reaction reported very rarely with ELECON Lotion 0.1% include burning, folliculitis, acneiform reaction, pruritus and signs of skin atrophy.

Local adverse reaction reported very rarely with ELECON Ointment 0.1% include burning, pruritus, tingling/stingling and signs of skin atrophy.

The following local adverse reaction have been reported infrequently with the use of another topical corticosteroid: Burning, pruritus, irritation, dry skin, folliculitis, hypertrichosis, acneiform eruption, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria.

If irritation or sensitization develops with the use of ELECON products, treatment should be discontinued and appropriate therapy instituted.
In the presence of the infection, use of an appropriate antifungal or antibacterial agent should be instituted.

Any of the side effects that have been reported following systemic use of corticosteroids, including adrenal suppression, may also occur with topical corticosteroids, especially in infants and children.

Systemic absorption of topical corticosteroids will be increased if extensive body surface areas are treated or if the occlusive technique is used. Suitable precautions should be taken under these conditions or when long term use is anticipated, particularly in infants and children.Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced hypothalamic-pituitary axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weigh ratio. Use of topical corticosteroids in children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with growth and development of children.

Corticosteroid therapy can be used if therapy with less toxic drugs is not effective.

ELECON products are not for ophthalmic use.

USE DURING PREGNANCY AND IN NURSING WOMEN: Since safe use of ELECON products in pregnant women has not been established, topical corticosteroids should be used during pregnancy only if the potential benefit justifies potential risk to the fetus. Drugs of this class should not be used on pregnant patients in large amount or for prolonged periods of time.

It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, a decision should be made whether to discontinue nursing or to continue the drug, taking into account the importance of the drug to the mother.

Over dosage:
Symtomps: Excessive, prolonged use of topical corticosteroids can suppres pituitary-adrenal function resulting in secondary adrenal insufficiency.
Treatment: Appropriate symptomatic treatment is indicated.Acute hypercorticoid symptoms are virtually reversible. Treat electrolyte imbalance, if necessary. In cases of chronic toxicity, slow withdrawal of corticosteroids is advised.

Store between 2 and 30 degree Celsius in tightly closed container.


Obat Terkait

1 Komentar

  1. oleh di
    Bermanfaat: / Tidak bermanfaat:



    Apakah komentar ini bermanfaat bagi Anda?

Beri Komentar

Email Anda tidak akan dipublikasikan. Kolom yang wajib diisi ditandai *

Informasi yang tersedia di DechaCare.com diambil dari berbagai sumber dan tidak dimaksudkan sebagai pengganti nasihat, saran, konsultasi ataupun kunjungan kepada dokter Anda. Kunjungi dokter Anda bila masalah kesehatan atau sakit Anda berlanjut. DechaCare.com tidak bertanggung jawab atas segala dampak yang terjadi atas penggunaan/penyalahgunaan informasi yang disajikan.

Berlangganan Informasi

Dapatkan informasi kesehatan dan informasi obat terupdate dengan mendaftarkan email Anda.

Copyright © 2018 DechaCare.com. Design website oleh adiacipta.com

Back to Top